HLB Pharmaceutical Co. Ltd Cash Flow-to-Debt Ratio
HLB Pharmaceutical Co. Ltd cash flow-to-debt ratio. HLB Pharmaceutical Co. Ltd (047920) has a Cash Flow-to-Debt Ratio of 0.04x as of September 2025, meaning its operating cash flow of ₩1.86 Billion could theoretically repay 0% of its total liabilities (₩46.98 Billion) in one year. Check HLB Pharmaceutical Co. Ltd total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of HLB Pharmaceutical Co. Ltd (2014–2024)
Cash flow-to-debt ratio of HLB Pharmaceutical Co. Ltd from 2014 to 2024. Historical debt coverage capacity for HLB Pharmaceutical Co. Ltd across 11 annual periods. Check HLB Pharmaceutical Co. Ltd earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
HLB Pharmaceutical Co. Ltd Cash Flow-to-Debt Ratio by Year (2014–2024)
HLB Pharmaceutical Co. Ltd cash flow-to-debt ratio by year from 2014 to 2024. Year-by-year debt coverage analysis for HLB Pharmaceutical Co. Ltd. For the full cash flow conversion analysis, see cash efficiency ratio of HLB Pharmaceutical Co. Ltd.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.16x | ₩6.84 Billion | ₩41.53 Billion | ▲ +147.8% |
| 2023 | -0.34x | ₩-18.32 Billion | ₩53.20 Billion | ▼ -601.0% |
| 2022 | -0.05x | ₩-2.76 Billion | ₩56.25 Billion | ▼ -83.1% |
| 2021 | -0.03x | ₩-1.32 Billion | ₩49.25 Billion | ▼ -344.3% |
| 2020 | -0.01x | ₩-403.36 Million | ₩66.80 Billion | ▼ -113.0% |
| 2019 | 0.05x | ₩1.35 Billion | ₩29.04 Billion | ▲ +150.9% |
| 2018 | -0.09x | ₩-1.78 Billion | ₩19.42 Billion | ▼ -168.9% |
| 2017 | -0.03x | ₩-784.30 Million | ₩23.04 Billion | ▼ -256.8% |
| 2016 | -0.01x | ₩-213.11 Million | ₩22.34 Billion | ▲ +84.3% |
| 2015 | -0.06x | ₩-769.59 Million | ₩12.67 Billion | ▼ -165.4% |
| 2014 | 0.09x | ₩1.54 Billion | ₩16.62 Billion | — |